- Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis
This study is testing a new medicine, JNJ-95475939, for adults who have moderate to severe eczema (atopic dermatitis). Researchers want to see if it helps improve skin symptoms compared to a dummy medicine or an existing treatment called Dupixent.
For: Moderate to Severe Atopic DermatitisSpain · Poland · Germany - Active not recruitingPHASE2
A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)
This study is testing a new medicine called JNJ-95475939 for people with moderate to severe eczema (atopic dermatitis). Researchers want to see if it works better than a dummy medicine (placebo) to improve skin and reduce itching.
For: Dermatitis, AtopicUnited States · Argentina · Brazil